Outlook Therapeutics Inc
Research Outlook Therapeutics Inc (OTLK) on Bullrun: market cap USD 109.45M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOTLK
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 109.45M
- Financial periodQ2 2026
- RevenueUSD 8.70K
- Net income-USD 20.32M
- Free cash flow-USD 21.01M
- Gross margin-95.0%
Valuation Snapshot
latest market cap is USD 109.45M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.41M | -USD 62.42M | -USD 51.83M | 4.0% | -1.79 | USD 8.08M | USD 30.19M | -USD 32.19M |
| FY2024 | USD 0 | -USD 75.37M | -USD 68.79M | n/a | -4.06 | USD 14.93M | USD 29.74M | -USD 73.08M |
| FY2023 | USD 0 | -USD 58.98M | -USD 42.97M | n/a | -4.72 | USD 23.39M | USD 35.56M | -USD 14.44M |
| FY2022 | USD 0 | -USD 66.05M | -USD 56.67M | n/a | -0.31 | USD 17.40M | USD 10.96M | USD 8.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 109.45M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 102.00M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 47.07M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 102.54M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 274.97M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 304.99M | n/a | n/a | n/a |
About Outlook Therapeutics Inc
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Outlook Therapeutics Inc's market cap?
Outlook Therapeutics Inc's market capitalization is USD 109.45M.
What does Outlook Therapeutics Inc do?
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc.